Recently launched drugs contributed significantly to Eli Lilly & Co.'s third quarter growth, but it remains to be seen whether those assets plus recent job cuts and the proposed sale or spinout of its animal health business will be enough to offset competitive pressures for pharmaceutical products.
Lilly continues to meet its goal of 5% annual revenue growth through 2020, helped by a 9% year-over-year increase to...








